Cellebrite DI Ltd.
CLBT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $4,615 | $1,647 | $797 | $1,155 |
| - Cash | $192 | $190 | $88 | $146 |
| + Debt | $11 | $14 | $15 | $0 |
| Enterprise Value | $4,434 | $1,471 | $724 | $1,009 |
| Revenue | $401 | $325 | $271 | $246 |
| % Growth | 23.4% | 20.1% | 9.9% | – |
| Gross Profit | $339 | $272 | $220 | $204 |
| % Margin | 84.4% | 83.6% | 81.3% | 82.7% |
| EBITDA | $68 | -$65 | $130 | $89 |
| % Margin | 16.8% | -19.9% | 48.1% | 36.3% |
| Net Income | -$283 | -$81 | $121 | $71 |
| % Margin | -70.5% | -24.9% | 44.6% | 29% |
| EPS Diluted | -1.35 | -0.43 | 0.59 | 0.44 |
| % Growth | -214% | -172.9% | 34.1% | – |
| Operating Cash Flow | $132 | $102 | $21 | $36 |
| Capital Expenditures | -$11 | -$8 | -$9 | -$8 |
| Free Cash Flow | $122 | $94 | $11 | $28 |